General Proximity
General Proximity has built a generalized, mechanism-agnostic proximity discovery engine that systematically identifies effector proteins—chaperones, adaptors, trafficking proteins, and PTM readers/writers/erasers—to enable precise control of protein function. The platform maps the "effectome" and manipulates proximity topology to achieve outcomes like activation, refolding, re-localization, or degradation of previously undruggable targets. Its OmniTAC platform is being applied to develop therapeutics for cancer, cardiometabolic disease, neurodegeneration, and longevity.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Most medicines act on a limited set of well-understood targets, leaving a vast number of disease-causing proteins "undruggable" with current approaches. Traditional drug discovery methods lack a systematic way to control protein function beyond active-site inhibition, limiting therapeutic options for many diseases.
Solution
General Proximity has built the first generalized, mechanism-agnostic proximity discovery engine that systematically identifies effector proteins—chaperones, adaptor proteins, trafficking proteins, and PTM readers/writers/erasers—that regulate biology through proximity. The platform maps the 'effectome,' the set of all proteins that modulate other proteins, and discovers the most powerful proximity mechanisms for any given target. By manipulating a protein's proximity topology, General Proximity enables activation, refolding, re-localization, re-programming, functional modulation, or degradation of target proteins. This approach allows for nearly arbitrary control of protein function and biology, enabling the development of highly-efficacious proximity therapeutics for targets previously beyond the reach of medicine. The company's proprietary OmniTAC platform enables precise and selective modification of disease-driving proteins, creating therapeutic opportunities for traditionally undruggable targets.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to develop programmable proximity therapeutics for previously undruggable targets, as well as researchers focused on protein-level control of biology.
Features
- Mechanism-agnostic discovery engine unbiased by pre-existing drug mechanisms
- Systematic identification of effector proteins including chaperones, adaptors, trafficking proteins, and PTM readers/writers/erasers
- Map of the 'effectome'—the complete set of proteins that modulate other proteins to control biology
- Proximity topology manipulation enabling diverse downstream outcomes: activation, refolding, re-localization, re-programming, functional modulation, and degradation
- OmniTAC platform for precise and selective modification of disease-driving proteins
- Platform applicable across targets regardless of biological pathway or disease area, with initial focus on oncology, cardiometabolic disease, neurodegenerative diseases, and longevity